DDD

3D Systems is swapping all $92M of 2030 notes for new debt, shares, and cash.

3D Systems posts strong revenue growth but remains loss-making despite EBITDA improvement.

3D Systems expands EU dental reach via BioSummer Dental, but financial impact remains unquantified.

3D Systems and Precision Resource are doubling additive manufacturing capacity with two new US sites.

3D Systems expands U.S. manufacturing by 50,000 sq ft, targeting aerospace and defense markets.

3D Systems adds 50,000 sq ft in Colorado, boosting total capacity to 270,000 sq ft.

Metavista3D secures CDN$6M financing, but funds arrive slowly and benefits are unproven.

Metavista3D signed a non-binding MOU for potential U.S. retail deployment, but no deals yet.

3D Systems posts another quarterly loss despite modest healthcare growth and a major share issuance.

3D Systems’ Saudi JV gets military license, but financial impact remains unproven.

FDA clearance is real, but financial impact for NYSE:DDD remains unquantified and speculative.

3D Systems and Elmet tout aerospace 3D printing, but commercial impact remains unproven.

Leadership hire signals ambition, but no financial or commercial proof is provided.

This is a promotional event notice, not a material investment signal.

3D Systems is raising cash, but offers no details on how it will use it.

3D Systems is raising cash, but offers no details on why or what comes next.

3D Systems is improving, but most growth claims lack hard numbers and remain unproven.

Big promises, little proof—watch for real numbers before buying the hype.

3D Systems touts a Formula 1 win, but offers no hard numbers or financial clarity.

Certification is real, but commercial impact and financial upside remain unproven and distant.